I am a follower of Jesus, husband, father, brother and physician | Pers Views Only |
Knox City, Texas
Joined August 2011
- Tweets1K
- Following648
- Followers918
- Likes2.8K
Thomas Hutson, DO, PharmD, PhD FACP retweeted
The FDA approval of perioperative EVP in muscle invasive bladder cancer makes platinum eligable somewhat redundant. It creates a paradigm shift in the disease and a is landmark moment . The principle of ‘EVP first, ask questions later’ becomes more relevant. The next questions are i) can we cure most of these patients without surgery and ii) how much systemic therapy is needed? @Annals_Oncology @OncoAlert
Thomas Hutson, DO, PharmD, PhD FACP retweeted
Bir günde iki FDA onayı.
Prostat kanserinde capivasertib kombinasyonu.
Böbrek kanserinde belzutifan ve pembrolizumab kombinasyonu.
Her iki çalışmada da @AnkaraUni olarak yer almaktan büyük mutluluk duyuyoruz.
Bugün en büyük teşekkür hastalarımıza ve yakınlarına.
Bilime inandıkları, güvendikleri ve bu yolu bizimle yürüdükleri için.
Çünkü bilim, onların cesaretiyle ilerliyor.
@US_FDA @OncoAlert @AnkaraUni @Ankaratip1945 @yekeduz_emre @necdetunuvar @ZehraAycan4
Thomas Hutson, DO, PharmD, PhD FACP retweeted
Renal cancer highlights #ASCO26 1) RAMPART - adjuvant durva/tremi vs durva vs surveillance. How much does CTLA4 help? 2) Is ctDNA useful post surgery in RCC (KN565 data)? 3) Does radium-223 help in bone mets patients? (a RII study) 4) Data on 2 VEGF+PD1 combination single arm studies in papillary RCC.
Thomas Hutson, DO, PharmD, PhD FACP retweeted
Bladder cancer highlights #ASCO26
1) Data for 3 Nectin4/Topo1 ADCs showing efficacy (LY4052031 , LY4101174, SHR-A2102). Can we sequence these drugs after EV? 2) Data from EV302/303 for EVP showing longer term outcomes and QOL 3) adjuvant QOL data for adjuvant pembro (AMBASSADOR) or atezo (IM011) 4) updated data for durvalumab in MIBC (with RT) & NMIBC (POTOMAC). @OncoAlert
Thomas Hutson, DO, PharmD, PhD FACP retweeted
Follow along with @OncoAlert as @nataliagandur, @scocmem, @weoncologists, & I cover GU highlights at #ASCO26! @LauraBukavinaMD @MoningiShalini @HemOncFellows @NazliDizman @AnaVManana @CleClinicMD @CleClinicUro
The OncoAlert🚨 GU faculty’s TOP 10 abstracts In GU Oncology for #ASCO26 are here — selected by our leads and finalized through a Delphi voting process with our senior GU cancer experts across #ProstateCancer #KidneyCancer #BladderCancer .
A snapshot of what will shape GU oncology at #ASCO26 👇
1️⃣ LBA5007 — TALAPRO-3
Talazoparib + enzalutamide vs placebo + enzalutamide in mCSPC with HRR alterations
2️⃣ LBA1 — PROTEUS
Perioperative apalutamide + ADT vs ADT in high-risk localized/locally advanced prostate cancer (final Phase 3)
3️⃣ 5001 — ENZAMET genomic analysis
Decipher >0.85 to identify benefit from adding docetaxel to ADT + enzalutamide
4️⃣ LBA4511 — KEYNOTE-564 ctDNA
ctDNA dynamics in RCC treated with adjuvant pembrolizumab vs placebo
5️⃣ 4502 — RAMPART
Durvalumab vs active monitoring after resection in RCC (Phase 3 RCT)
6️⃣ 4500 — RADICAL (A031801)
Radium-223 + cabozantinib in RCC with bone metastases
7️⃣ 4507 — EV-302 long-term follow-up
Enfortumab vedotin + pembrolizumab vs chemotherapy in 1L LA/mUC
8️⃣ 4513 — AMBASSADOR (A031501)
HRQoL with adjuvant pembrolizumab vs observation in high-risk MIBC
9️⃣ 4503 — SAKK 06/19
Perioperative intravesical rBCG + chemo-IO strategy in MIBC (primary analysis)
🔟 4510 — KEYNOTE-905
HRQoL with perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible MIBC
Leads
@nataliagandur
@scocmem
@AmandaNizamMD
@WeOncologists
Senior Faculty
@montypal @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @neerajaiims @amerseburger @Silke_Gillessen
@tompowles1 @AndreaNecchi @cdanicas @AOmlin
Pinging
@crisbergerot @HHammersMD @ravikanesvaran @sonpavde @drenriquegrande @scserendipity1 @EfstathiouEleni @BraunMDPhD @brian_rini
Thomas Hutson, DO, PharmD, PhD FACP retweeted
Most #ASCO26 abstracts are scheduled for release today at 5:00PM ET. Some GU highlights ⬇️.
Many more anticipated GU presentations beyond this list. Looking forward to seeing everyone next week!
asco.org/abstracts
@ASCO @NazliDizman @AnaVManana @OncBrothers @HemOncFellows @CleClinicMD @CleClinicUro
Wonderfully blessed and honored to hood my mentee, Jaret Shook PharmD at my alma mater medical school Ohio University Heritage College of Osteopathic Medicine. He is a new daddy with a beautiful wife and family, off to Urology residency Cleveland Clinic Akron General Hospital He is the future of healthcare. Brea Shook Sandy Shook Brandon Shook Grant Shook Brent Shook #familytriptoohio #PharmDsfromONU #SigEps
Thomas Hutson, DO, PharmD, PhD FACP retweeted
⚡️ @NEJM - Perioperative enfortumab vedotin + pembrolizumab improves outcomes in muscle-invasive bladder cancer.
In KEYNOTE-905:
• 2-year EFS: 74.7% vs 39.4% (HR 0.40)
• OS: HR 0.50
• pCR: 57.1% vs 8.6%
A potential new standard in cisplatin-ineligible patients.
#BladderCancer #Immunotherapy
nejm.org/doi/full/10.1056/NE…
Thomas Hutson, DO, PharmD, PhD FACP retweeted
More is not always more in RCC.
In Phase 3 LITESPARK-012, adding belzutifan or quavonlimab to pembrolizumab-lenvatinib did not beat the doublet on PFS or OS at interim!
🧬🧬🎯Is precision now more urgent than intensification?
merck.com/news/merck-and-eis…
@Merck @EisaiGlobalOnc @EisaiUS @kidneycan @KidneyCancer @IKCCorg @OncoAlert
Thomas Hutson, DO, PharmD, PhD FACP retweeted
Just Out: Couldn’t have said it better. @IMDConline Very Favorable risk is a new category of metastatic @kidneycancer that needs VEGF-based therapy. IO alone may not be enough. Great work @ZarbaMartin1 @DrChoueiri @tompowles1 @DrRanaMcKay @eddy_saad @UCalgaryMed @JAMANetworkOpen
Not all IMDC favorable-risk RCC is the same.
Tier 1 ("very favorable"): KPS ≥90%, diagnosis to treatment ≥3 yrs, no brain/liver/bone mets. Median OS 79 vs 54 months for tier 2, and molecularly more angiogenic, less immunogenic.
➡️ JAMA Netw Open (n=641 IMDC favorable-risk mRCC): "very favorable" tier
➡️ IO-IO 2-yr OS 73.1% vs 89.1% IO-VE vs 92.4% VEGF-TT in tier 1 (HR 3.64, p=0.005)
➡️ Molecular data: tier 1 tumors are less immunogenic
Why this matters: 💡 IMDC favorable risk isn't a single population very favorable patients have cold tumors and may need VEGF-based regimens🩺
@DrDanielHeng #KidneyCancer #RCC #GUonc #FOAMonc
Wow. 😮
NEWS FROM INDUSTRY: LITESPARK-012 Update in Kidney Cancer
Source: News Release MERCK
buff.ly/d8alIAa
Update on the Phase 3 LITESPARK-012 results in advanced renal cell carcinoma. Triplet therapy with pembrolizumab , lenvatinib , and belzutifan. The trial failed🚫 to improve progression-free or overall survival versus pembrolizumab plus lenvatinib. Safety was consistent with prior data. #KidneyCancer
@montypal @crisbergerot @DrDanielHeng @apolo_andrea @DrChoueiri @PGrivasMDPhD @TiansterZhang @HHammersMD @ravikanesvaran @neerajaiims @amerseburger @sonpavde @drenriquegrande @scserendipity1 @Silke_Gillessen @EfstathiouEleni @tompowles1 @BraunMDPhD @nataliagandur @cdanicas @brian_rini @AOmlin
#OncoAlertAF
@nataliagandur @realbowtiedoc @Onco_Cifu88 @scocmem
@AmandaNizamMD
Thomas Hutson, DO, PharmD, PhD FACP retweeted
⚡️ In BCG-naïve high-risk NMIBC, immunotherapy escalation is promising—but not for everyone.
BCG remains a highly effective benchmark, and any added benefit must be balanced against immune toxicity, cost, and the risk of overtreatment.
Selectivity matters.
#BladderCancer #Immunotherapy @EurUrolOncol
euoncology.europeanurology.c…
Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905 trial) nejm.org/doi/full/10.1056/NE…
Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nejm.org/doi/full/10.1056/NE…
#Oncology
ALT The Kaplan–Meier estimates of event-free survival
Thomas Hutson, DO, PharmD, PhD FACP retweeted
📢 Our work on KIM1 in advanced RCC is now published in @EUplatinum
We conducted an exploratory analysis of KIM1 in pRCC & ccRCC to assess its role as a prognostic and on-treatment monitoring biomarker.
@OncoAlert @tompowles1 @VincentWenxinXu
sciencedirect.com/science/ar…
Thomas Hutson, DO, PharmD, PhD FACP retweeted
During @ASCO #GU26, 2 positive RPIII will be presented: LS011 and LS022. Both adding HIF2 inhibitor (@NobelPrize 2019 story with @kaelin_lab et al) to standard of care. Both Trials positive. Saturday Feb 28 will be the day RCC achieves another milestone.
@OncoAlert @kidneycan @KidneyCancer @motzermd @NCCN
